Soleno Therapeutics Inc.
SLNO | NASDAQ
$53.01
$0 (0.00%)
May 15, 2026, 4:00 PM ET · Market open
Company Profile
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Key Executives
| Name | Position |
|---|---|
| Anish Bhatnagar | Chairman, President & CEO |
| Jennifer Fulk | Chief Financial Officer |
| Dairine Dempsey | Senior Vice President of Europe |
| James H. MacKaness | Executive Officer |
| Jesse Schumaker | General Counsel |
| Kristen Yen | Senior Vice President of Global Clinical Operations and Patient Advocacy |
| Lauren Budesheim | Senior Vice President of People |
| Meredith Manning | Chief Commercial Officer |
| Michael Huang | Senior Vice President of Clinical Development |
| Mitchell Nagao | Senior Vice President of Medical Affairs |
| Neil Cowen | Senior Vice President of New Product Planning |
| Patricia C. Hirano | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2026 | 10-K/A | [Amend] Annual Report |
| Apr 29, 2026 | SC TO-T/A | [Amend] Filing |
| Apr 28, 2026 | SC TO-T/A | [Amend] Filing |
| Apr 28, 2026 | SC 14D9/A | [Amend] Filing |
| Apr 24, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Apr 20, 2026 | SC 14D9 | Filing |
| Apr 20, 2026 | SC TO-T | Filing |
| Apr 07, 2026 | 8-K | Current Report |
| Apr 07, 2026 | SC TO-C | Filing |
| Apr 06, 2026 | SC14D9C | Filing |
Soleno Therapeutics Inc.
| Country | United States |
| IPO Date | Nov 12, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Anish Bhatnagar |
Contact Details
203 Redwood Shores Parkway Redwood City,
California 94065 United States
Stock Details
| Ticker Symbol | SLNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001484565 |
| CUSIP Number | 834203200 |
| ISIN Number | US8342033094 |
| SIC Code | 3845 |
Recent News
- 5 months ago / prnewswire.comSLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman
- 5 months ago / newsfilecorp.comSOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
- 5 months ago / globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO
- 5 months ago / prnewswire.comSLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
- 5 months ago / globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors
- 5 months ago / prnewswire.comSLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
- 5 months ago / newsfilecorp.comSOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
- 5 months ago / globenewswire.comSOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline
- 5 months ago / globenewswire.comSOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
- 5 months ago / newsfilecorp.comSLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Add to Watchlist
Select watchlists to add or remove SLNO